About denovoSkin

After severe wounding, human skin fails to regenerate and physiologically heals by scar formation. Worldwide, millions of people suffer from severe skin defects or diseases requiring surgical interventions to restore skin function.

Existing therapies frequently leave these patients with permanent, painful, disfiguring, and debilitating scars. Scars may impair movement and growth, and often require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Severe skin defects significantly affect quality of life in a long term, along with the economic burden for the health-care system. Human skin is composed of an outer epidermis, a dermis and a hypodermis. The components of the dermis control and regulate scarring. Today, standard of care consists in harvesting a thin layer of healthy patient’s skin, which contains the epidermis but only remnants of the dermis. Since sufficient dermis is missing, these grafts often develop into scars. Furthermore, in severe cases, where most of the skin has been destroyed (e.g. burns), the shortage of healthy skin, that needs to be harvested to heal the wounds, represents a real clinical challenge.

In 2001 a team of the University-Children’s Hospital Zurich led by Prof. Dr. M. Meuli and Prof. Dr. E. Reichmann pursued the vision of bio-engineering personalized dermo-epidermal skin grafts, using a small sample of patients’ own cells. One of the developed products, denovoSkin now developed by CUTISS, is the result of more than fifteen years of research.



08-03-22 - Press Release

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator
read more

More News